Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
about
Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?The Crossroads of Geriatric Cardiology and Cardio-OncologyCohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base--a refined prostate cancer trajectory.Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer.Differences in Hypercholesterolemia and Atherogenesis Induced by Common Androgen Deprivation Therapies in Male Mice.Long-term Toxicity of Cancer Treatment in Older PatientsAdverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.Group-based exercise in daily clinical practice to improve physical fitness in men with prostate cancer undergoing androgen deprivation therapy: study protocol.Cause of Death in Korean Men with Prostate Cancer: an Analysis of Time Trends in a Nationwide Cohort.The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer.Current and future strategies for the nutritional management of cardiometabolic complications of androgen deprivation therapy for prostate cancer.Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer.The use of exercise interventions to overcome adverse effects of androgen deprivation therapy.A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.Assessing the cardiovascular risk of hormonal therapy in patients with prostate cancer.Cardiovascular toxicities of systemic treatments of prostate cancer.Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden.Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men.Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer.Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer.Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.Metabolic changes in patients with prostate cancer during androgen deprivation therapy.Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer.Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer.Long-term consequences of ovarian ablation for premenopausal breast cancer.Prenatal Exposure to DEHP Induces Neuronal Degeneration and Neurobehavioral Abnormalities in Adult Male Mice.Proton Beam Therapy Alone for Intermediate- or High-Risk Prostate Cancer: An Institutional Prospective Cohort Study.Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report.Medical management of metastatic prostate cancer
P2860
Q26749088-73C48A27-FB04-4F77-9A96-E55153B4334BQ26778666-4F7C93F6-29FB-408C-BF9C-42ED336BD983Q35867402-1FD3CEE2-A93C-4605-907A-7CCE964D22FAQ36474222-64C4F8D8-AB29-4B58-B7BB-9216A34F5F51Q36714085-C7347DC7-421F-40EC-883F-1BA5C45C29C4Q36821673-C4AE8E70-0AE2-4A0C-91AD-9ADF03A83CCEQ36854835-9508B840-4BE4-4BB0-B530-9DD46FD47F41Q37063622-2142F537-9AEC-4827-913B-0C8961481F00Q37323456-6C0EEB63-83BA-4AB8-8D7C-0F0A3CEF75E4Q37708169-2200F789-CCF4-4AA7-B11F-755C5AAD3DD9Q38671819-8B3C4FA8-14E6-431E-A471-955923F6297AQ38707724-ADD9CB55-ADA1-4FAA-BC2A-55FD0BC0E20DQ38817011-05CE5F12-D63B-45F5-9374-495F07C7E3F0Q38946665-54AECF0E-EFB9-49E2-A291-8AA49AC766DDQ38993745-A2B53DA0-C9C5-4A80-84EA-8F794269D9C1Q39002111-846F4112-A6CD-4760-BB6B-67687E735849Q39247489-9D7CC62F-8CD6-49CE-BEC1-0BA35022C780Q39282641-E1FA0E36-EF4F-487B-AB3A-0FB7CE90F8A0Q39756984-53738418-0C4F-49ED-899F-08679BB719E2Q40164167-3BD48E20-4304-40F5-BF5E-70E6420E5AF9Q40391176-1D9EEAA0-9443-49EE-A92D-D3176C1891F7Q40400351-1B4CB995-41FB-42BE-B0FD-F1448BCE43CEQ41189502-D03F92DA-2836-4CF4-B84F-BE7DAD8B7C1CQ46415794-8545C7BD-796D-4345-8DD5-20B8AD08C722Q47610526-0E3B55F1-8A1F-4EFA-AF38-88822EA7572EQ47754588-A168014A-EB35-4141-896E-5034BD71B4D1Q47936579-F88525B3-F7E5-41C3-BA2E-AF96264E25D0Q48194331-3CD46133-FA5D-4DB2-BF2C-30729A525A77Q50135459-8EBBC790-8A2E-4C44-9FFB-0A4B65E796B1Q50848449-651ED373-F426-4AA3-83DF-E2BB4A266132Q52567187-CC01D208-3EA4-4C8F-BC7C-8EBA5A3A4080Q52593552-4695DFDD-8C87-420E-9AA4-F3494952250AQ53414816-0A9A6FE9-1AC4-4CE7-8C0F-9251C7F5C02DQ58588895-AB864E8F-0E9A-4975-A0E6-1C8E7DA02F21
P2860
Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Risk and timing of cardiovascu ...... y in men with prostate cancer.
@en
type
label
Risk and timing of cardiovascu ...... y in men with prostate cancer.
@en
prefLabel
Risk and timing of cardiovascu ...... y in men with prostate cancer.
@en
P50
P356
P1476
Risk and timing of cardiovascu ...... y in men with prostate cancer.
@en
P2093
Pär Stattin
Sean O'Farrell
P304
P356
10.1200/JCO.2014.59.1792
P407
P577
2015-03-02T00:00:00Z